EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction

Mickaël Machicoane, Marika Tonellato, Marica Zainotto, Paul Onillon, Marco Stazi, Mattia Dal Corso, Aram Megighian, Ornella Rossetto, Jean-Marc Le Doussal, Marco Pirazzini iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17367 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Mickaël Machicoane and 9 co-authors. Institution: Fastox Pharma SA, Lausanne, Switzerland. Major MEDLINE topics: Botulinum Toxins, Type A, Neuromuscular Junction. 94 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fastox Pharma, Università degli Studi di Padova, Italian Ministry of University and Research.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Purpose Botulinum neurotoxin type A1 (BoNT/A) is one of the most potent neurotoxins known. At the same time, it is also one of the safest therapeutic agents used for the treatment of several human disorders and in aesthetic medicine. Notwithstanding great effectiveness, strategies to accelerate the onset and prolong BoNT/A action would significantly ameliorate its pharmacological effects with beneficial outcomes for clinical use. Experimental Approach Here, we combined BoNT/A with two fast‐acting inhibitors of excitation–contraction coupling inhibitors (ECCI), either the μ‐conotoxin CnIIIC or dantrolene, and tested the effect of their co‐injection on a model of hind‐limb paralysis in rodents using behavioural, biochemical, imaging and electrophysiological assays. Key Results The BoNT/A‐ECCI combinations accelerated the onset of muscle relaxation. Surprisingly, they also potentiated the peak effect and extended the duration of the three BoNT/A commercial preparations OnabotulinumtoxinA, AbobotulinumtoxinA and IncobotulinumtoxinA. ECCI co‐injection increased the number of BoNT/A molecules entering motoneuron terminals, which induced a faster and greater cleavage of SNAP‐25 during the onset and peak phases, and prolonged the attenuation of nerve‐muscle neurotransmission during the recovery phase. We estimate that ECCI co‐injection yields a threefold potentiation in BoNT/A pharmacological activity. Conclusions and Implications Overall, our results show that the pharmacological activity of BoNT/A can be combined and synergized with other bioactive molecules and uncover a novel strategy to enhance the neuromuscular effects of BoNT/A without altering the neurotoxin moiety or intrinsic activity, thus maintaining its exceptional safety profile.

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type ANeuromuscular JunctionAnimalsMaleDantroleneConotoxinsRatsExcitation Contraction CouplingDrug SynergismSynaptosomal-Associated Protein 25ParalysisNeuromuscular AgentsRats, Sprague-DawleyRats, WistarMice

Author keywords

abobotulinumbotulinum neurotoxinconotoxindantroleneexcitation–contraction couplingincobotulinumneuromuscular junctiononabotulinumspasticity

Substances

Botulinum Toxins, Type ADantroleneConotoxinsSynaptosomal-Associated Protein 25incobotulinumtoxinANeuromuscular Agentsonabotulinum toxin AabobotulinumtoxinA

Authors and institutions

  • Fastox Pharma SA, Lausanne, Switzerland.
  • Department of Biomedical Sciences, University of Padova, Padova, Italy.
  • Padova Neuroscience Center, University of Padova, Padova, Italy.
  • Institute of Neuroscience, Italian Research Council, University of Padova, Padova, Italy.
  • Interdepartmental Research Center of Myology CIR-Myo, University of Padova, Padova, Italy.

ORCID profiles: Marco Pirazzini

Funding

  • Fastox Pharma
  • Università degli Studi di Padova
  • Italian Ministry of University and Research
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Cite

APA

Machicoane, M., Tonellato, M., Zainotto, M., Onillon, P., Stazi, M., Corso, M. D., Megighian, A., Rossetto, O., Le Doussal, J. M., & Pirazzini, M. (2025). Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction. British Journal of Pharmacology. https://doi.org/10.1111/bph.17367

Vancouver

Machicoane M, Tonellato M, Zainotto M, Onillon P, Stazi M, Corso MD, et al. Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction. British Journal of Pharmacology. 2025. doi:10.1111/bph.17367

BibTeX
@article{Machicoane2025,
  author = {Machicoane, Mickaël and Tonellato, Marika and Zainotto, Marica and Onillon, Paul and Stazi, Marco and Corso, Mattia Dal and Megighian, Aram and Rossetto, Ornella and Le Doussal, Jean-Marc and Pirazzini, Marco},
  title = {Excitation–contraction coupling inhibitors potentiate the actions of botulinum neurotoxin type A at the neuromuscular junction},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17367}
}
Start for free →